Amgen Inc. Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, before Tax (Deprecated 2013-01-31)
Amgen Inc. (AMGN) reported Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, before Tax (Deprecated 2013-01-31) of -$67.00 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-03.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax · last filed 2013-05-03
- Amgen Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, before tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was -$67.00M.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, before tax (deprecated 2013-01-31) for fiscal 2012 was -$132.00M.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, before tax (deprecated 2013-01-31) for fiscal 2011 was -$154.00M.
- Amgen Inc. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, before tax (deprecated 2013-01-31) for fiscal 2010 was -$90.00M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, before Tax (Deprecated 2013-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, before Tax (Deprecated 2013-01-31) 12 month |
|---|---|---|
| 2013-03-31 | -$67.00M 10-Q · filed 2013-05-03 | |
| 2012-12-31 | -$132.00M 10-K · filed 2013-02-27 | |
| 2011-12-31 | -$154.00M 10-K · filed 2013-02-27 | |
| 2010-12-31 | -$90.00M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |